ProfileGDS5678 / 1423202_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 85% 85% 88% 85% 84% 86% 88% 86% 86% 85% 87% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.471586
GSM967853U87-EV human glioblastoma xenograft - Control 26.4876485
GSM967854U87-EV human glioblastoma xenograft - Control 36.3549285
GSM967855U87-EV human glioblastoma xenograft - Control 47.0069188
GSM967856U87-EV human glioblastoma xenograft - Control 56.3370985
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0419584
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3691886
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7545488
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4217786
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5819886
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2992185
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.710287
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5324686
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5799687